Send to

Choose Destination
Sci Signal. 2018 Oct 16;11(552). pii: eaat2214. doi: 10.1126/scisignal.aat2214.

Biased antagonism of CXCR4 avoids antagonist tolerance.

Author information

Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, USA.
Department of Surgery, Burn and Shock Trauma Research Institute, Loyola University Chicago, Chicago, IL, USA.
Department of Surgery, Morsani College of Medicine, University of South Florida, College of Medicine, Tampa, FL, USA.
Department of Biochemistry, Research Centre, Sainte-Justine Hospital, Montréal, Quebec, Canada.
Department of Molecular and Cellular Biochemistry, Indiana University, Bloomington, IN, USA.
Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Division of Bioscience and Biotechnology, Biomolecular Informatics Center, Konkuk University, Seoul 05029, Republic of Korea.
Cancer and Inflammation Program, National Cancer Institute, P.O. Box B, Frederick, MD, USA.
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, USA.


Repeated dosing of drugs targeting G protein-coupled receptors can stimulate antagonist tolerance, which reduces their efficacy; thus, strategies to avoid tolerance are needed. The efficacy of AMD3100, a competitive antagonist of the chemokine receptor CXCR4 that mobilizes leukemic blasts from the bone marrow into the blood to sensitize them to chemotherapy, is reduced after prolonged treatment. Tolerance to AMD3100 increases the abundance of CXCR4 on the surface of leukemic blasts, which promotes their rehoming to the bone marrow. AMD3100 inhibits both G protein signaling by CXCR4 and β-arrestin1/2-dependent receptor endocytosis. We demonstrated that biased antagonists of G protein-dependent chemotaxis but not β-arrestin1/2 recruitment and subsequent receptor endocytosis avoided tolerance. The peptide antagonist X4-2-6, which is derived from transmembrane helix 2 and extracellular loop 1 of CXCR4, limited chemotaxis and signaling but did not promote CXCR4 accumulation on the cell surface or cause tolerance. The activity of X4-2-6 was due to its distinct mechanism of inhibition of CXCR4. The peptide formed a ternary complex with the receptor and its ligand, the chemokine CXCL12. Within this complex, X4-2-6 released the portion of CXCL12 critical for receptor-mediated activation of G proteins but enabled the rest of the chemokine to recruit β-arrestins to the receptor. In contrast, AMD3100 displaced all components of the chemokine responsible for CXCR4 activation. We further identified a small molecule with similar biased antagonist properties to those of X4-2-6, which may provide a viable alternative to patients when antagonist tolerance prevents drugs from reaching efficacy.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center